title: Regulation of slowly activating potassium current (I(Ks)) by secretin in rat pancreatic acinar cells.
abstract: 1. The secretagogue-activated K(+) conductance is indispensable for the electrogenic Cl(-) secretion in exocrine tissue. In this study, we investigated the effect of secretin and other cAMP-mediated secretagogues on the slowly activating voltage-dependent K(+) current (I(Ks)) of rat pancreatic acinar cells (RPAs) with the whole-cell patch clamp technique. 2. Upon depolarization, RPAs showed I(Ks) superimposed upon the instantaneous background outward current. Secretin (5 nM), vasoactive intestinal peptide (5 nM), forskolin (5 microM), isoprenaline (10 microM) or 3-isobutyl-1-methylxanthine (IBMX, 0.1 mM) increased the amplitude of I(Ks) two- to fourfold. 3. The physiological concentration of secretin (50 pM) had a relatively weak effect on I(Ks) (160 % increase), which was significantly enhanced by transient co-stimulation with carbachol (CCh) (10 microM). However, the secretin-induced production of cAMP, which was measured by enzyme-linked immunosorbent assay, was not augmented by co-stimulation with CCh. 4. This study is the first to demonstrate the regulation of K(+) channels in RPAs by cAMP-mediated agonists. The I(Ks) channel is a common target for both Ca(2+) and cAMP agonists. The vagal stimulation under the physiological concentration of secretin facilitates I(Ks), which provides an additional driving force for Cl(-) secretion.
authors.affiliation: Department of Physiology, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea.
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
authors.forename: J K
authors.initials: JK
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Pavenstädt
authors.forename: R
authors.initials: R
authors.lastname: Greger
authors.forename: M J
authors.initials: MJ
authors.lastname: Hug
authors.forename: M
authors.initials: M
authors.lastname: Bleich
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D020013:Calcium Signaling / Q000502:physiology; D002217:Carbachol / Q000494:pharmacology; D002712:Chlorides / Q000378:metabolism; D018679:Cholinergic Agonists / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005765:Gastrointestinal Agents / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D010179:Pancreas / Q000166:cytology / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D015221:Potassium Channels / Q000378:metabolism*; D051381:Rats; D012633:Secretin / Q000378:metabolism / Q000494:pharmacology*; D013449:Sulfonamides; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D002712:Chlorides; D018679:Cholinergic Agonists; D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D007546:Isoquinolines; D010726:Phosphodiesterase Inhibitors; D015221:Potassium Channels; D013449:Sulfonamides; D012633:Secretin; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D002217:Carbachol; D000242:Cyclic AMP; D007545:Isoproterenol; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D015056:1-Methyl-3-isobutylxanthine